- Home
- PROF vs ACRS Comparison
PROF vs ACRS Comparison
Compare PROF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROF
- ACRS
- Stock Information
- Founded
- PROF N/A
- ACRS 2012
- Country
- PROF Canada
- ACRS United States
- Employees
- PROF N/A
- ACRS N/A
- Industry
- PROF Medical/Dental Instruments
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- PROF Health Care
- ACRS Health Care
- Exchange
- PROF Nasdaq
- ACRS Nasdaq
- Market Cap
- PROF 149.7M
- ACRS 165.7M
- IPO Year
- PROF N/A
- ACRS 2015
- Fundamental
- Price
- PROF $5.90
- ACRS $1.42
- Analyst Decision
- PROF Strong Buy
- ACRS Strong Buy
- Analyst Count
- PROF 2
- ACRS 8
- Target Price
- PROF $11.50
- ACRS $9.71
- AVG Volume (30 Days)
- PROF 43.9K
- ACRS 1.3M
- Earning Date
- PROF 08-07-2025
- ACRS 08-06-2025
- Dividend Yield
- PROF N/A
- ACRS N/A
- EPS Growth
- PROF N/A
- ACRS N/A
- EPS
- PROF N/A
- ACRS N/A
- Revenue
- PROF $11,862,000.00
- ACRS $17,777,000.00
- Revenue This Year
- PROF $71.17
- ACRS N/A
- Revenue Next Year
- PROF $134.25
- ACRS $11.77
- P/E Ratio
- PROF N/A
- ACRS N/A
- Revenue Growth
- PROF 75.01
- ACRS N/A
- 52 Week Low
- PROF $3.90
- ACRS $1.05
- 52 Week High
- PROF $11.42
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- PROF 49.59
- ACRS 57.34
- Support Level
- PROF $5.84
- ACRS $1.34
- Resistance Level
- PROF $6.22
- ACRS $1.66
- Average True Range (ATR)
- PROF 0.45
- ACRS 0.09
- MACD
- PROF -0.09
- ACRS 0.01
- Stochastic Oscillator
- PROF 6.28
- ACRS 69.55
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.